Logo image of NUVA

NUVASIVE INC (NUVA) Stock Fundamental Analysis

NASDAQ:NUVA - Nasdaq - US6707041058 - Common Stock - Currency: USD

39.75  -0.91 (-2.24%)

After market: 39.88 +0.13 (+0.33%)

Fundamental Rating

4

Overall NUVA gets a fundamental rating of 4 out of 10. We evaluated NUVA against 189 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of NUVA while its profitability can be described as average. NUVA has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

NUVA had positive earnings in the past year.
NUVA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: NUVA reported negative net income in multiple years.
NUVA had a positive operating cash flow in each of the past 5 years.
NUVA Yearly Net Income VS EBIT VS OCF VS FCFNUVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M 200M

1.2 Ratios

With a decent Return On Assets value of 1.36%, NUVA is doing good in the industry, outperforming 75.38% of the companies in the same industry.
The Return On Equity of NUVA (3.19%) is better than 76.38% of its industry peers.
NUVA has a Return On Invested Capital of 3.43%. This is in the better half of the industry: NUVA outperforms 76.38% of its industry peers.
NUVA had an Average Return On Invested Capital over the past 3 years of 2.87%. This is significantly below the industry average of 8.22%.
The last Return On Invested Capital (3.43%) for NUVA is above the 3 year average (2.87%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.36%
ROE 3.19%
ROIC 3.43%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
NUVA Yearly ROA, ROE, ROICNUVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5 -5 10

1.3 Margins

NUVA's Profit Margin of 2.32% is fine compared to the rest of the industry. NUVA outperforms 74.37% of its industry peers.
In the last couple of years the Profit Margin of NUVA has declined.
Looking at the Operating Margin, with a value of 6.73%, NUVA is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
In the last couple of years the Operating Margin of NUVA has declined.
The Gross Margin of NUVA (71.66%) is better than 82.41% of its industry peers.
NUVA's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.73%
PM (TTM) 2.32%
GM 71.66%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
NUVA Yearly Profit, Operating, Gross MarginsNUVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NUVA is destroying value.
The number of shares outstanding for NUVA has been increased compared to 1 year ago.
Compared to 1 year ago, NUVA has an improved debt to assets ratio.
NUVA Yearly Shares OutstandingNUVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
NUVA Yearly Total Debt VS Total AssetsNUVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 1.91 indicates that NUVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
NUVA has a Altman-Z score of 1.91. This is comparable to the rest of the industry: NUVA outperforms 57.29% of its industry peers.
NUVA has a Debt/Equity ratio of 0.89. This is a neutral value indicating NUVA is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.89, NUVA is doing worse than 78.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z 1.91
ROIC/WACC0.42
WACC8.11%
NUVA Yearly LT Debt VS Equity VS FCFNUVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M 400M 600M 800M

2.3 Liquidity

NUVA has a Current Ratio of 1.25. This is a normal value and indicates that NUVA is financially healthy and should not expect problems in meeting its short term obligations.
NUVA has a Current ratio of 1.25. This is amonst the worse of the industry: NUVA underperforms 89.45% of its industry peers.
NUVA has a Quick Ratio of 1.25. This is a bad value and indicates that NUVA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.65, NUVA is not doing good in the industry: 93.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 0.65
NUVA Yearly Current Assets VS Current LiabilitesNUVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

NUVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.61%, which is quite good.
The Earnings Per Share has been growing slightly by 0.62% on average over the past years.
The Revenue has been growing slightly by 4.44% in the past year.
The Revenue has been growing slightly by 3.20% on average over the past years.
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%

3.2 Future

The Earnings Per Share is expected to grow by 14.32% on average over the next years. This is quite good.
Based on estimates for the next years, NUVA will show a small growth in Revenue. The Revenue will grow by 6.89% on average per year.
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NUVA Yearly Revenue VS EstimatesNUVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
NUVA Yearly EPS VS EstimatesNUVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 19.88, which indicates a rather expensive current valuation of NUVA.
86.93% of the companies in the same industry are more expensive than NUVA, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 29.62, NUVA is valued a bit cheaper.
A Price/Forward Earnings ratio of 15.23 indicates a correct valuation of NUVA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NUVA indicates a rather cheap valuation: NUVA is cheaper than 88.44% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of NUVA to the average of the S&P500 Index (22.70), we can say NUVA is valued slightly cheaper.
Industry RankSector Rank
PE 19.88
Fwd PE 15.23
NUVA Price Earnings VS Forward Price EarningsNUVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NUVA indicates a rather cheap valuation: NUVA is cheaper than 93.47% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11
NUVA Per share dataNUVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

NUVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of NUVA may justify a higher PE ratio.
NUVA's earnings are expected to grow with 14.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.42
PEG (5Y)32.2
EPS Next 2Y14.82%
EPS Next 3Y14.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NUVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVASIVE INC

NASDAQ:NUVA (8/31/2023, 8:10:26 PM)

After market: 39.88 +0.13 (+0.33%)

39.75

-0.91 (-2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-02 2023-08-02/amc
Earnings (Next)11-07 2023-11-07/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners1.99%
Ins Owner Change0%
Market Cap2.08B
Analysts70.91
Price Target50.72 (27.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.04%
Min EPS beat(2)0.41%
Max EPS beat(2)7.68%
EPS beat(4)2
Avg EPS beat(4)-2.68%
Min EPS beat(4)-17.19%
Max EPS beat(4)7.68%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.05%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)1.16%
Revenue beat(4)1
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.16%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.53%
PT rev (3m)2.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.88%
EPS NY rev (1m)0%
EPS NY rev (3m)2.33%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 19.88
Fwd PE 15.23
P/S 1.7
P/FCF N/A
P/OCF 14.94
P/B 2.34
P/tB 24.74
EV/EBITDA 11
EPS(TTM)2
EY5.03%
EPS(NY)2.61
Fwd EY6.57%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)2.66
OCFY6.69%
SpS23.38
BVpS17.02
TBVpS1.61
PEG (NY)1.42
PEG (5Y)32.2
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 3.19%
ROCE 5.48%
ROIC 3.43%
ROICexc 3.59%
ROICexgc 6.59%
OM 6.73%
PM (TTM) 2.32%
GM 71.66%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
ROICexc(3y)4.12%
ROICexc(5y)4.87%
ROICexgc(3y)17.94%
ROICexgc(5y)16.07%
ROCE(3y)3.71%
ROCE(5y)5.01%
ROICexcg growth 3Y3.59%
ROICexcg growth 5Y-1.31%
ROICexc growth 3Y-7.11%
ROICexc growth 5Y-4.99%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
F-Score7
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA 3.58
Cap/Depr 101.93%
Cap/Sales 11.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 0.65
Altman-Z 1.91
F-Score7
WACC8.11%
ROIC/WACC0.42
Cap/Depr(3y)82.61%
Cap/Depr(5y)85.69%
Cap/Sales(3y)10.64%
Cap/Sales(5y)10.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%
EBIT growth 1Y45.07%
EBIT growth 3Y-11.68%
EBIT growth 5Y-7.06%
EBIT Next Year96.6%
EBIT Next 3Y33.66%
EBIT Next 5Y25.87%
FCF growth 1Y-102.72%
FCF growth 3Y-34.34%
FCF growth 5Y-14.37%
OCF growth 1Y-39.92%
OCF growth 3Y-10.42%
OCF growth 5Y-0.91%